2024
Topography of mutational signatures in non-small cell lung cancer: emerging concepts, clinical applications, and limitations
Jayakrishnan R, Kwiatkowski D, Rose M, Nassar A. Topography of mutational signatures in non-small cell lung cancer: emerging concepts, clinical applications, and limitations. The Oncologist 2024, 29: 833-841. PMID: 38907669, PMCID: PMC11449018, DOI: 10.1093/oncolo/oyae091.Peer-Reviewed Original ResearchMutational signaturesNon-small cell lung cancerBase substitutionsNon-small lung cancerCell lung cancerLung cancerSingle base substitutionsDoublet base substitutionsResponse to personalized treatmentGenomics effortsMutational signature analysisGenesis of cancerLoss of mismatch repairResponse to therapyMutational processesDamaged DNAAPOBEC activityMismatch repairRepair mechanismsTumor evolutionEndogenous processesMutationsPersonalized treatmentCancerTobacco smoke
2023
Time to Diagnosis and Treatment of Non-small Cell Lung Cancer in Patients Undergoing Lung Cancer Screening
Bernstein E, DeRycke E, Han L, Bastian L, Bade B, Lerz K, Kravetz J, Carino M, Rose M, Akgun K, Cain H. Time to Diagnosis and Treatment of Non-small Cell Lung Cancer in Patients Undergoing Lung Cancer Screening. 2023, a2734-a2734. DOI: 10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a2734.Peer-Reviewed Original Research
2018
QUADRUPLE THREAT: A phase II trial of RRx-001 followed by etoposide-platinum re-challenge in previously treated small cell lung cancer.
Padda S, Brzezniak C, Waqar S, Wakelee H, Ma P, Rose M, Reid T, Spira A, Wong E, Zeman K, Oronsky B, Abrouk N, Morgensztern D. QUADRUPLE THREAT: A phase II trial of RRx-001 followed by etoposide-platinum re-challenge in previously treated small cell lung cancer. Journal Of Clinical Oncology 2018, 36: e20575-e20575. DOI: 10.1200/jco.2018.36.15_suppl.e20575.Peer-Reviewed Original Research